News

The National Hemophilia Foundation (NHF) is working with the bleeding disorders community to envision our future for the next decade, and they…

Gene therapy for hemophilia remains a very active area of research, although it may take longer than expected. To discuss this, join…

Remember a few simple recommendations to stay safe during the pandemic and a possible second wave of infection: practice good hygiene by…

The NHF is saddened by the loss of life and destruction of communities due to catastrophic fires in the west and a…

Perhaps a more difficult job than discovering a safe vaccine for COVID-19 is producing enough to widely inoculate the public – and…

Although posted on the CDC website on Friday, September 18th and reported in the popular press, a major change in the guidance from…

One of our most important civil liberties is the right to vote. With your vote, you have the power to influence public…

Policy and Advocacy work is increasingly important at the state level. In an effort to keep you informed about the work happening…

A recent commentary published in the journal Haemophilia, posits that while clinical trials for hemophilia gene therapy approach conclusion, there remain significant unanswered…

Sanofi recently announced results from their phase 1/2a EXTEN-A trial for their investigational therapy BIVV001, which were published in the New England Journal…

CSL Behring recently announced that they are discontinuing Mononine®, the company’s human plasma-derived factor therapy indicated for the prevention and control of…

The National Hemophilia Foundation will be holding our quarterly Board of Directors meeting on Saturday, October 10th at 9:00 AM EDT. The Board…

In the fall of last year Genentech reported that during a routine examination of batches of Hemlibra®, they found translucent particles composed…

The National Hemophilia Foundation (NHF) and Hemophilia Federation of America (HFA) continue to follow up on issues arising from the recent recall of Stimate (desmopressin)…

The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council (MASAC) issued two new documents, which were adopted by NHF’s Board of…

by: Debbie de la Riva The collective pursuit to control the spread of coronavirus has resulted in an enormous challenge for the…

Routine healthcare visits are being held up because of the pandemic, so many parents are missing their children’s annual hemophilia treatment center…

NHF’s Bleeding Disorders Conference was fully virtual this year and included more than 50 sessions. Those sessions are all available on-demand until…

Last month, BioMarin learned that approval for their investigational hemophilia A gene therapy was not forthcoming but would in fact be delayed…

On September 1, 2020, NHF and HFA learned that  Mylan N.V. is conducting a voluntary nationwide recall of  four lots of Tranexamic Acid Injection,…

The National Hemophilia Foundation (NHF) has received a five-year cooperative agreement from the Centers from Disease Control and Prevention (CDC). The collaboration,…

BioMarin is committed to updating the community regarding our ongoing gene therapy clinical trial program in hemophilia A. BioMarin’s investigational gene therapy…

Biomarin announced that they received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on August 18th for their…

Novo Nordisk has announced that clinical trials for their investigational subcutaneous therapy concizumab will resume after an approximate five month pause, initiated…